News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Mesynthes Obtains U.S. FDA 510(k) Clearance for Endoform Dermal Template

2/2/2010 6:38:08 AM

Bookmark and Share

WELLINGTON, New Zealand--(BUSINESS WIRE)--Mesynthes, a privately held regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Endoform Dermal Template™. Endoform, a proprietary extracellular matrix biomaterial, provides a unique biologic template for tissue regeneration.

“FDA marketing clearance for Endoform Dermal Template™ paves the way for commercial launch into the U.S. dermal market and establishes our Endoform™ platform as a new medical biomaterial for tissue repair and reconstruction,” said Dr. Brian Ward, Chief Executive Officer.

Mesynthes’s Endoform™ technology utilizes a proprietary extracellular matrix biomaterial containing a complex mixture of important biological molecules, including structural and adhesive proteins, such as collagens, elastin, fibronectin and laminin, and glycosaminoglycans.

“In tissue regeneration, it is now well recognized that a diverse mix of extracellular matrix components is important for orchestrating a regenerative response. These components provide important structure, signals, and substrates to cells within the healing tissue,” said Dr. Ward. “Once applied to the wound bed, the Endoform Dermal Template™ provides a uniquely supportive environment to guide the growth of cells and new tissue. Over time, Endoform™ is completely replaced by the patient’s own tissue. Clinically, the impact of applying extracellular matrix within a chronic wound is to restart the stalled healing process and stimulate new tissue growth in the wound bed. In acute wounds, extracellular matrix replaces lost dermis, advancing the wound healing process and reducing contracture.”

Chronic wounds are difficult to heal, require ongoing care, and risk complications that can lead to amputation. In the United States, the treatment costs of chronic and complex wounds have been estimated to be $20 billion per year, which creates a significant burden on the healthcare system. Endoform Dermal Template™ provides a new tool to address this important issue.

About the Endoform Dermal Template™

Endoform Dermal Template™ is presented as a sterile dry sheet in a peel pouch and is strong and easy to handle in a dry or wet state. It is applied directly to the wound bed, then rehydrated, covered with a non-adherent dressing, and secured in place. Endoform™ is quick and easy to apply, available off-the shelf, and doesn’t require special storage.

Endoform Dermal Template™ is intended for the management of a wide variety of wounds including:

* partial and full-thickness wounds * pressure ulcers * venous ulcers * diabetic ulcers * chronic vascular ulcers * tunnelled/undermined wounds * surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence) * trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) * draining wounds

Endoform’s unique features include its innate biology, strength, size, usability, and versatility. Also, Mesynthes’ proprietary processing and ovine (sheep)-derived biomaterial combine to add a new level of xeno-biological safety and cultural acceptability.

Mesynthes is developing a suite of medical devices for applications in regenerative medicine including products for wound care and soft tissue reconstruction based on the Endoform™ platform.

About Mesynthes

Mesynthes Ltd. is a privately held regenerative medicine company that has developed Endoform™, a novel extracellular matrix platform for soft tissue repair and reconstruction. For more information on Mesynthes and its technology and products, please visit our web site at


Mesynthes Brian Ward, +64 21 727646 Chief Executive Officer or Kureczka/Martin Associates Joan Kureczka, +1-415-821-2413

Read at

comments powered by Disqus